CluenexRepligen RGEN
Repligen scores average on business quality (4.9 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Repligen does
Repligen sells bioprocessing technologies and consumable components to life sciences companies and drug manufacturers. Its primary segments supply critical tools for biological drug production, engineered to fit seamlessly into existing manufacturing workflows. The company is leaning into expanding its addressable market in advanced therapeutics, supported by recent 52-week highs despite overarching sector concerns.
- What it does best
Repligen excels at generating strong cash conversion, posting a free cash flow margin of 52% which places it in the top quartile of its sector. This high conversion is hard to copy because its filtration and chromatography components are deeply embedded in validated client drug manufacturing processes, creating massive switching costs.
- The main risk
Market concerns regarding high valuations and broader sector pressures pose a risk to the stock, which recently hit 52-week highs despite weak return on equity metrics like an ROE of 2.0%. If sentiment shifts, the extreme valuation multiples risk sharp compression.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin of 8.8% and a net margin of 5.4% point to modest profitability, though the free cash flow margin hits an elite 52%. Scaling brings strong cash generation despite lower operating margins.
Repligen builds its narrow moat around high switching costs for biopharma developers who lock in its filtration tech. Its gross margin of 53.9% sits below peers like TECH at 66.3%, limiting pricing power.
Revenue growth bounced back to 16.4% on $785.0 million in sales, accelerating from flat historical periods like 2023-2024. This top-line expansion beats peer contractions seen at companies like AVTR.
With cash of $768.0 million and net debt of -$226.0 million, the balance sheet features a low debt-to-equity of 0.3. Free cash flow sits at $110.0 million, though interest coverage of 2.9x is tight. Overall, financial stability is steady.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on RGEN
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Repligen scores average on the Cluenex quality check (4.9 of 10), measured against its own industry. Profitability is fair, moat weak, growth steady and financial health fair.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 3, 2026, before the open.
See RGEN today
- Today's verdict on RGEN, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Repligen (RGEN)”, https://cluenex.com/stocks/rgen/, data as of Oct 10, 2026.